German Medical Law

Sources of German Medical Law

German medical law (Medizinrecht) draws from multiple legal sources. The Bürgerliches Gesetzbuch (BGB) governs the medical treatment contract (Arztvertrag), which is a contract for services (Dienstvertrag) under § 611 BGB, with specific duties defined by case law and the Patients’ Rights Act 2013. The Social Code Book V (SGB V) regulates the statutory health insurance system (Gesetzliche Krankenversicherung, GKV). The Physicians’ Professional Code (Berufsordnung), issued by the State Medical Chambers (Landesärztekammern), sets professional standards. The Pharmaceuticals Act (Arzneimittelgesetz, AMG) and the Medical Devices Act (Medizinproduktegesetz, MPG) regulate products.

Statutory Health Insurance

The GKV covers approximately 90% of the population under the principle of solidarity (Solidaritätsprinzip). Contributions are income-based and shared between employers and employees. The system is administered by non-profit sickness funds (Krankenkassen). The Gemeinsamer Bundesausschuss (Federal Joint Committee) determines the benefit catalogue. Private health insurance (Private Krankenversicherung, PKV) is available for higher-income individuals, civil servants, and the self-employed, offering risk-based premiums and broader coverage options.

Medical Malpractice

Medical malpractice liability arises from the treatment contract and the tort of negligence (§§ 280, 823 BGB). The patient must prove a treatment error (Behandlungsfehler) and causation, but the burden of proof is eased in several respects. Courts shift the burden to the physician for gross errors (grober Behandlungsfehler), where the error is clearly contrary to established medical practice, and for failures to document treatment adequately. The patient has the right to inspect medical records (Einsichtsrecht) under § 630g BGB.

Out-of-Court Resolution

Expert commissions and arbitration boards (Gutachterkommissionen und Schlichtungsstellen) operated by the State Medical Chambers provide an alternative to litigation. These bodies assess whether a treatment error occurred and offer a non-binding opinion. The process is free for patients and reduces the burden on the courts, though either party may subsequently pursue litigation.

Informed Consent and Advance Directives

Informed consent (Einwilligung) is a foundational principle requiring the patient’s consent after adequate information about the nature, significance, scope, and risks of the proposed treatment. The treating physician must provide verbal information in a timely manner. The advance directive (Patientenverfügung), codified in § 1901a BGB, allows a competent person to specify medical treatment preferences in the event of future incapacity. The living will is binding on physicians and carers. For incapacitated patients without an advance directive, a guardian (Betreuer) is appointed by the Betreuungsgericht to make medical decisions in the patient’s best interests.

Medical Research and Transplantation

Medical research is regulated by the AMG and the Medical Devices Act, implementing EU Clinical Trials Regulation 536/2014. The Helsinki Declaration and the guidelines of the German Medical Association inform ethical standards. The Transplantation Act (Transplantationsgesetz, TPG) governs organ donation and transplantation, adopting the opting-in model with the requirement of explicit consent, supplemented by the decision solution (Entscheidungslösung) requiring citizens to document their organ donation preference.

Pharmaceutical Law

Pharmaceutical products require authorisation from the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) or the Paul Ehrlich Institute for vaccines and blood products. The AMG sets requirements for clinical trials, manufacturing, labelling, pharmacovigilance, and the classification of prescription and over-the-counter medicines. The pricing of pharmaceuticals is regulated through the AMNOG process (Arzneimittelmarktneuordnungsgesetz), requiring manufacturers to demonstrate additional benefit over existing treatments for reimbursement.